Call it irritation, exasperation, or frustration, but biosimilar manufacturers and payers alike are feeling it, as the fight over drug patents has barred the way to approval for yet another biosimilar for a costly biologic. In this case, Sandoz’s Erelzi™, which was approved by the Food and Drug Administration on August 30, 2016, has been … Continue reading Frustration Mounts as Sandoz’s Etanercept Biosimilar Launch Delayed into 2018 →